Regulatory watch: Innovative drug availability in China

Liming Shao¹, Lili Xu², Qiu Li², Ranjana Chakravarthy³, Ziling Yang^{3

4}, Kenneth I Kaitin³

Affiliations

¹ Fudan Center for Study of Pharmaceuticals and Healthcare Strategy and the School of Pharmacy, Fudan University, 826 Zhangheng Road, Zhangjiang Hi-tech Park, Pudong, Shanghai 201203, China.
² Fudan Center for Study of Pharmaceuticals and Healthcare Strategy, 826 Zhangheng Road, Zhangjiang Hi-tech Park, Pudong, Shanghai 201203, China.
³ Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
⁴ Tufts CSDD in 2015.

Liming Shao et al. Nat Rev Drug Discov. 2016 Nov.

. 2016 Nov;15(11):739-740.

doi: 10.1038/nrd.2016.200. Epub 2016 Oct 21.

Liming Shao¹, Lili Xu², Qiu Li², Ranjana Chakravarthy³, Ziling Yang^{3

4}, Kenneth I Kaitin³

¹ Fudan Center for Study of Pharmaceuticals and Healthcare Strategy and the School of Pharmacy, Fudan University, 826 Zhangheng Road, Zhangjiang Hi-tech Park, Pudong, Shanghai 201203, China.
² Fudan Center for Study of Pharmaceuticals and Healthcare Strategy, 826 Zhangheng Road, Zhangjiang Hi-tech Park, Pudong, Shanghai 201203, China.
³ Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
⁴ Tufts CSDD in 2015.

No abstract available

Comment in

Impact of regulatory system changes on the availability of innovative drugs in China.
Ge Q, Xu L, DiMasi JA, Kaitin KI, Shao L. Ge Q, et al. Nat Rev Drug Discov. 2023 May;22(5):344-345. doi: 10.1038/d41573-023-00058-0. Nat Rev Drug Discov. 2023. PMID: 37059845 No abstract available.